nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2C19—Teniposide—lymphatic system cancer	0.163	0.268	CbGbCtD
Levomilnacipran—ABCB1—Mitoxantrone—lymphatic system cancer	0.0922	0.151	CbGbCtD
Levomilnacipran—CYP3A4—Cytarabine—lymphatic system cancer	0.0802	0.131	CbGbCtD
Levomilnacipran—CYP3A4—Teniposide—lymphatic system cancer	0.079	0.13	CbGbCtD
Levomilnacipran—ABCB1—Vincristine—lymphatic system cancer	0.0634	0.104	CbGbCtD
Levomilnacipran—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0552	0.0906	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—lymphatic system cancer	0.0384	0.063	CbGbCtD
Levomilnacipran—CYP3A4—Vincristine—lymphatic system cancer	0.038	0.0623	CbGbCtD
Levomilnacipran—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00168	0.0043	CcSEcCtD
Levomilnacipran—Neutropenia—Carmustine—lymphatic system cancer	0.00167	0.00428	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00163	0.00418	CcSEcCtD
Levomilnacipran—Dyspnoea—Teniposide—lymphatic system cancer	0.00161	0.00413	CcSEcCtD
Levomilnacipran—Neutropenia—Vincristine—lymphatic system cancer	0.00159	0.00409	CcSEcCtD
Levomilnacipran—Dysuria—Vincristine—lymphatic system cancer	0.00159	0.00409	CcSEcCtD
Levomilnacipran—Infection—Fludarabine—lymphatic system cancer	0.00158	0.00404	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00157	0.00403	CcSEcCtD
Levomilnacipran—Decreased appetite—Teniposide—lymphatic system cancer	0.00157	0.00402	CcSEcCtD
Levomilnacipran—Vomiting—Mechlorethamine—lymphatic system cancer	0.00156	0.00399	CcSEcCtD
Levomilnacipran—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00156	0.00399	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00155	0.00398	CcSEcCtD
Levomilnacipran—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00155	0.00398	CcSEcCtD
Levomilnacipran—Urinary tract infection—Carmustine—lymphatic system cancer	0.00155	0.00397	CcSEcCtD
Levomilnacipran—Rash—Mechlorethamine—lymphatic system cancer	0.00154	0.00396	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00154	0.00396	CcSEcCtD
Levomilnacipran—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00154	0.00395	CcSEcCtD
Levomilnacipran—Weight decreased—Vincristine—lymphatic system cancer	0.00154	0.00395	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00153	0.00393	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00153	0.00392	CcSEcCtD
Levomilnacipran—Flushing—Bleomycin—lymphatic system cancer	0.00152	0.0039	CcSEcCtD
Levomilnacipran—Anorexia—Fludarabine—lymphatic system cancer	0.00151	0.00388	CcSEcCtD
Levomilnacipran—Weight decreased—Mitoxantrone—lymphatic system cancer	0.0015	0.00385	CcSEcCtD
Levomilnacipran—Proteinuria—Methotrexate—lymphatic system cancer	0.0015	0.00385	CcSEcCtD
Levomilnacipran—Protein urine present—Methotrexate—lymphatic system cancer	0.00148	0.00379	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00148	0.00378	CcSEcCtD
Levomilnacipran—Chills—Bleomycin—lymphatic system cancer	0.00147	0.00377	CcSEcCtD
Levomilnacipran—Nausea—Mechlorethamine—lymphatic system cancer	0.00145	0.00373	CcSEcCtD
Levomilnacipran—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00144	0.00369	CcSEcCtD
Levomilnacipran—Urticaria—Teniposide—lymphatic system cancer	0.00143	0.00368	CcSEcCtD
Levomilnacipran—Abdominal pain—Teniposide—lymphatic system cancer	0.00143	0.00366	CcSEcCtD
Levomilnacipran—Body temperature increased—Teniposide—lymphatic system cancer	0.00143	0.00366	CcSEcCtD
Levomilnacipran—Paraesthesia—Fludarabine—lymphatic system cancer	0.00143	0.00365	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00142	0.00365	CcSEcCtD
Levomilnacipran—Hallucination—Carmustine—lymphatic system cancer	0.00142	0.00365	CcSEcCtD
Levomilnacipran—Dyspnoea—Fludarabine—lymphatic system cancer	0.00141	0.00363	CcSEcCtD
Levomilnacipran—Haematuria—Mitoxantrone—lymphatic system cancer	0.00141	0.00362	CcSEcCtD
Levomilnacipran—Oedema peripheral—Carmustine—lymphatic system cancer	0.00141	0.00361	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Carmustine—lymphatic system cancer	0.0014	0.0036	CcSEcCtD
Levomilnacipran—Dyspepsia—Fludarabine—lymphatic system cancer	0.0014	0.00358	CcSEcCtD
Levomilnacipran—Decreased appetite—Fludarabine—lymphatic system cancer	0.00138	0.00354	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00137	0.00351	CcSEcCtD
Levomilnacipran—Fatigue—Fludarabine—lymphatic system cancer	0.00137	0.00351	CcSEcCtD
Levomilnacipran—Hallucination—Vincristine—lymphatic system cancer	0.00136	0.00348	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00136	0.00348	CcSEcCtD
Levomilnacipran—Constipation—Fludarabine—lymphatic system cancer	0.00136	0.00348	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00135	0.00345	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00134	0.00344	CcSEcCtD
Levomilnacipran—Urethral disorder—Vincristine—lymphatic system cancer	0.00134	0.00343	CcSEcCtD
Levomilnacipran—Eye disorder—Carmustine—lymphatic system cancer	0.00134	0.00342	CcSEcCtD
Levomilnacipran—Hypersensitivity—Teniposide—lymphatic system cancer	0.00133	0.00341	CcSEcCtD
Levomilnacipran—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00133	0.00341	CcSEcCtD
Levomilnacipran—Flushing—Carmustine—lymphatic system cancer	0.00133	0.0034	CcSEcCtD
Levomilnacipran—Asthenia—Teniposide—lymphatic system cancer	0.0013	0.00332	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00129	0.0033	CcSEcCtD
Levomilnacipran—Pruritus—Teniposide—lymphatic system cancer	0.00128	0.00327	CcSEcCtD
Levomilnacipran—Leukopenia—Bleomycin—lymphatic system cancer	0.00128	0.00327	CcSEcCtD
Levomilnacipran—Cystitis—Methotrexate—lymphatic system cancer	0.00127	0.00326	CcSEcCtD
Levomilnacipran—Cardiac disorder—Vincristine—lymphatic system cancer	0.00127	0.00325	CcSEcCtD
Levomilnacipran—Body temperature increased—Fludarabine—lymphatic system cancer	0.00125	0.00322	CcSEcCtD
Levomilnacipran—Mental disorder—Carmustine—lymphatic system cancer	0.00125	0.00321	CcSEcCtD
Levomilnacipran—Malnutrition—Carmustine—lymphatic system cancer	0.00124	0.00319	CcSEcCtD
Levomilnacipran—Angiopathy—Vincristine—lymphatic system cancer	0.00124	0.00317	CcSEcCtD
Levomilnacipran—Diarrhoea—Teniposide—lymphatic system cancer	0.00124	0.00317	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00123	0.00315	CcSEcCtD
Levomilnacipran—Chest pain—Bleomycin—lymphatic system cancer	0.00121	0.00311	CcSEcCtD
Levomilnacipran—Mental disorder—Vincristine—lymphatic system cancer	0.0012	0.00306	CcSEcCtD
Levomilnacipran—Chills—Mitoxantrone—lymphatic system cancer	0.00119	0.00306	CcSEcCtD
Levomilnacipran—Bladder pain—Methotrexate—lymphatic system cancer	0.00119	0.00306	CcSEcCtD
Levomilnacipran—Vision blurred—Carmustine—lymphatic system cancer	0.00117	0.00301	CcSEcCtD
Levomilnacipran—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00117	0.003	CcSEcCtD
Levomilnacipran—Tremor—Carmustine—lymphatic system cancer	0.00117	0.00299	CcSEcCtD
Levomilnacipran—Infection—Bleomycin—lymphatic system cancer	0.00116	0.00296	CcSEcCtD
Levomilnacipran—Vomiting—Teniposide—lymphatic system cancer	0.00115	0.00294	CcSEcCtD
Levomilnacipran—Agitation—Carmustine—lymphatic system cancer	0.00114	0.00293	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00114	0.00292	CcSEcCtD
Levomilnacipran—Asthenia—Fludarabine—lymphatic system cancer	0.00114	0.00292	CcSEcCtD
Levomilnacipran—Rash—Teniposide—lymphatic system cancer	0.00114	0.00292	CcSEcCtD
Levomilnacipran—Dermatitis—Teniposide—lymphatic system cancer	0.00114	0.00292	CcSEcCtD
Levomilnacipran—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00113	0.0029	CcSEcCtD
Levomilnacipran—Headache—Teniposide—lymphatic system cancer	0.00113	0.0029	CcSEcCtD
Levomilnacipran—Pruritus—Fludarabine—lymphatic system cancer	0.00112	0.00288	CcSEcCtD
Levomilnacipran—Leukopenia—Carmustine—lymphatic system cancer	0.00111	0.00286	CcSEcCtD
Levomilnacipran—Anorexia—Bleomycin—lymphatic system cancer	0.00111	0.00284	CcSEcCtD
Levomilnacipran—Agitation—Vincristine—lymphatic system cancer	0.00109	0.0028	CcSEcCtD
Levomilnacipran—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00109	0.00279	CcSEcCtD
Levomilnacipran—Hypotension—Bleomycin—lymphatic system cancer	0.00109	0.00279	CcSEcCtD
Levomilnacipran—Diarrhoea—Fludarabine—lymphatic system cancer	0.00109	0.00278	CcSEcCtD
Levomilnacipran—Convulsion—Carmustine—lymphatic system cancer	0.00108	0.00276	CcSEcCtD
Levomilnacipran—Hypertension—Carmustine—lymphatic system cancer	0.00107	0.00275	CcSEcCtD
Levomilnacipran—Nausea—Teniposide—lymphatic system cancer	0.00107	0.00275	CcSEcCtD
Levomilnacipran—Leukopenia—Vincristine—lymphatic system cancer	0.00106	0.00273	CcSEcCtD
Levomilnacipran—Chest pain—Carmustine—lymphatic system cancer	0.00106	0.00272	CcSEcCtD
Levomilnacipran—Anxiety—Carmustine—lymphatic system cancer	0.00106	0.00271	CcSEcCtD
Levomilnacipran—Paraesthesia—Bleomycin—lymphatic system cancer	0.00104	0.00268	CcSEcCtD
Levomilnacipran—Dyspnoea—Bleomycin—lymphatic system cancer	0.00104	0.00266	CcSEcCtD
Levomilnacipran—Renal failure acute—Methotrexate—lymphatic system cancer	0.00104	0.00266	CcSEcCtD
Levomilnacipran—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00104	0.00265	CcSEcCtD
Levomilnacipran—Convulsion—Vincristine—lymphatic system cancer	0.00103	0.00264	CcSEcCtD
Levomilnacipran—Hypertension—Vincristine—lymphatic system cancer	0.00103	0.00263	CcSEcCtD
Levomilnacipran—Decreased appetite—Bleomycin—lymphatic system cancer	0.00101	0.00259	CcSEcCtD
Levomilnacipran—Infection—Carmustine—lymphatic system cancer	0.00101	0.00259	CcSEcCtD
Levomilnacipran—Vomiting—Fludarabine—lymphatic system cancer	0.00101	0.00259	CcSEcCtD
Levomilnacipran—Convulsion—Mitoxantrone—lymphatic system cancer	0.001	0.00257	CcSEcCtD
Levomilnacipran—Rash—Fludarabine—lymphatic system cancer	0.001	0.00256	CcSEcCtD
Levomilnacipran—Dermatitis—Fludarabine—lymphatic system cancer	0.001	0.00256	CcSEcCtD
Levomilnacipran—Hypertension—Mitoxantrone—lymphatic system cancer	0.000999	0.00256	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000995	0.00255	CcSEcCtD
Levomilnacipran—Headache—Fludarabine—lymphatic system cancer	0.000994	0.00255	CcSEcCtD
Levomilnacipran—Tachycardia—Carmustine—lymphatic system cancer	0.000991	0.00254	CcSEcCtD
Levomilnacipran—Chest pain—Mitoxantrone—lymphatic system cancer	0.000985	0.00252	CcSEcCtD
Levomilnacipran—Anxiety—Mitoxantrone—lymphatic system cancer	0.000982	0.00252	CcSEcCtD
Levomilnacipran—Anorexia—Carmustine—lymphatic system cancer	0.000968	0.00248	CcSEcCtD
Levomilnacipran—Infection—Vincristine—lymphatic system cancer	0.000963	0.00247	CcSEcCtD
Levomilnacipran—Nervous system disorder—Vincristine—lymphatic system cancer	0.000951	0.00244	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000949	0.00243	CcSEcCtD
Levomilnacipran—Hypotension—Carmustine—lymphatic system cancer	0.000949	0.00243	CcSEcCtD
Levomilnacipran—Nausea—Fludarabine—lymphatic system cancer	0.000943	0.00242	CcSEcCtD
Levomilnacipran—Infection—Mitoxantrone—lymphatic system cancer	0.000938	0.0024	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000937	0.0024	CcSEcCtD
Levomilnacipran—Shock—Mitoxantrone—lymphatic system cancer	0.000929	0.00238	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000925	0.00237	CcSEcCtD
Levomilnacipran—Urticaria—Bleomycin—lymphatic system cancer	0.000924	0.00237	CcSEcCtD
Levomilnacipran—Anorexia—Vincristine—lymphatic system cancer	0.000924	0.00237	CcSEcCtD
Levomilnacipran—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000922	0.00236	CcSEcCtD
Levomilnacipran—Body temperature increased—Bleomycin—lymphatic system cancer	0.00092	0.00236	CcSEcCtD
Levomilnacipran—Insomnia—Carmustine—lymphatic system cancer	0.000919	0.00235	CcSEcCtD
Levomilnacipran—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000917	0.00235	CcSEcCtD
Levomilnacipran—Irritability—Methotrexate—lymphatic system cancer	0.000914	0.00234	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000913	0.00234	CcSEcCtD
Levomilnacipran—Paraesthesia—Carmustine—lymphatic system cancer	0.000912	0.00234	CcSEcCtD
Levomilnacipran—Hypotension—Vincristine—lymphatic system cancer	0.000906	0.00232	CcSEcCtD
Levomilnacipran—Dyspnoea—Carmustine—lymphatic system cancer	0.000906	0.00232	CcSEcCtD
Levomilnacipran—Somnolence—Carmustine—lymphatic system cancer	0.000903	0.00231	CcSEcCtD
Levomilnacipran—Anorexia—Mitoxantrone—lymphatic system cancer	0.0009	0.00231	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000884	0.00227	CcSEcCtD
Levomilnacipran—Decreased appetite—Carmustine—lymphatic system cancer	0.000883	0.00226	CcSEcCtD
Levomilnacipran—Hypotension—Mitoxantrone—lymphatic system cancer	0.000882	0.00226	CcSEcCtD
Levomilnacipran—Insomnia—Vincristine—lymphatic system cancer	0.000877	0.00225	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000877	0.00225	CcSEcCtD
Levomilnacipran—Paraesthesia—Vincristine—lymphatic system cancer	0.000871	0.00223	CcSEcCtD
Levomilnacipran—Constipation—Carmustine—lymphatic system cancer	0.000869	0.00223	CcSEcCtD
Levomilnacipran—Breast disorder—Methotrexate—lymphatic system cancer	0.000865	0.00222	CcSEcCtD
Levomilnacipran—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000857	0.0022	CcSEcCtD
Levomilnacipran—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000848	0.00217	CcSEcCtD
Levomilnacipran—Decreased appetite—Vincristine—lymphatic system cancer	0.000843	0.00216	CcSEcCtD
Levomilnacipran—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000842	0.00216	CcSEcCtD
Levomilnacipran—Somnolence—Mitoxantrone—lymphatic system cancer	0.000839	0.00215	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000837	0.00215	CcSEcCtD
Levomilnacipran—Fatigue—Vincristine—lymphatic system cancer	0.000836	0.00214	CcSEcCtD
Levomilnacipran—Asthenia—Bleomycin—lymphatic system cancer	0.000835	0.00214	CcSEcCtD
Levomilnacipran—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000831	0.00213	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000831	0.00213	CcSEcCtD
Levomilnacipran—Constipation—Vincristine—lymphatic system cancer	0.000829	0.00213	CcSEcCtD
Levomilnacipran—Pruritus—Bleomycin—lymphatic system cancer	0.000823	0.00211	CcSEcCtD
Levomilnacipran—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000821	0.0021	CcSEcCtD
Levomilnacipran—Fatigue—Mitoxantrone—lymphatic system cancer	0.000814	0.00209	CcSEcCtD
Levomilnacipran—Constipation—Mitoxantrone—lymphatic system cancer	0.000808	0.00207	CcSEcCtD
Levomilnacipran—Abdominal pain—Carmustine—lymphatic system cancer	0.000803	0.00206	CcSEcCtD
Levomilnacipran—Body temperature increased—Carmustine—lymphatic system cancer	0.000803	0.00206	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000793	0.00203	CcSEcCtD
Levomilnacipran—Dysuria—Methotrexate—lymphatic system cancer	0.000774	0.00198	CcSEcCtD
Levomilnacipran—Neutropenia—Methotrexate—lymphatic system cancer	0.000774	0.00198	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000772	0.00198	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000769	0.00197	CcSEcCtD
Levomilnacipran—Body temperature increased—Vincristine—lymphatic system cancer	0.000767	0.00196	CcSEcCtD
Levomilnacipran—Abdominal pain—Vincristine—lymphatic system cancer	0.000767	0.00196	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000762	0.00195	CcSEcCtD
Levomilnacipran—Urticaria—Mitoxantrone—lymphatic system cancer	0.00075	0.00192	CcSEcCtD
Levomilnacipran—Hypersensitivity—Carmustine—lymphatic system cancer	0.000748	0.00192	CcSEcCtD
Levomilnacipran—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000746	0.00191	CcSEcCtD
Levomilnacipran—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000746	0.00191	CcSEcCtD
Levomilnacipran—Vomiting—Bleomycin—lymphatic system cancer	0.00074	0.0019	CcSEcCtD
Levomilnacipran—Rash—Bleomycin—lymphatic system cancer	0.000734	0.00188	CcSEcCtD
Levomilnacipran—Dermatitis—Bleomycin—lymphatic system cancer	0.000733	0.00188	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000731	0.00187	CcSEcCtD
Levomilnacipran—Asthenia—Carmustine—lymphatic system cancer	0.000729	0.00187	CcSEcCtD
Levomilnacipran—Hypersensitivity—Vincristine—lymphatic system cancer	0.000714	0.00183	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—lymphatic system cancer	0.000703	0.0018	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000698	0.00179	CcSEcCtD
Levomilnacipran—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000696	0.00178	CcSEcCtD
Levomilnacipran—Asthenia—Vincristine—lymphatic system cancer	0.000696	0.00178	CcSEcCtD
Levomilnacipran—Diarrhoea—Carmustine—lymphatic system cancer	0.000695	0.00178	CcSEcCtD
Levomilnacipran—Nausea—Bleomycin—lymphatic system cancer	0.000691	0.00177	CcSEcCtD
Levomilnacipran—Asthenia—Mitoxantrone—lymphatic system cancer	0.000678	0.00174	CcSEcCtD
Levomilnacipran—Dizziness—Carmustine—lymphatic system cancer	0.000672	0.00172	CcSEcCtD
Levomilnacipran—Diarrhoea—Vincristine—lymphatic system cancer	0.000663	0.0017	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—lymphatic system cancer	0.000662	0.0017	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000654	0.00168	CcSEcCtD
Levomilnacipran—Urethral disorder—Methotrexate—lymphatic system cancer	0.000649	0.00166	CcSEcCtD
Levomilnacipran—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000646	0.00166	CcSEcCtD
Levomilnacipran—Vomiting—Carmustine—lymphatic system cancer	0.000646	0.00166	CcSEcCtD
Levomilnacipran—Dizziness—Vincristine—lymphatic system cancer	0.000641	0.00164	CcSEcCtD
Levomilnacipran—Rash—Carmustine—lymphatic system cancer	0.00064	0.00164	CcSEcCtD
Levomilnacipran—Dermatitis—Carmustine—lymphatic system cancer	0.00064	0.00164	CcSEcCtD
Levomilnacipran—Headache—Carmustine—lymphatic system cancer	0.000636	0.00163	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000626	0.0016	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—lymphatic system cancer	0.000619	0.00159	CcSEcCtD
Levomilnacipran—Vomiting—Vincristine—lymphatic system cancer	0.000617	0.00158	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000615	0.00158	CcSEcCtD
Levomilnacipran—Rash—Vincristine—lymphatic system cancer	0.000611	0.00157	CcSEcCtD
Levomilnacipran—Dermatitis—Vincristine—lymphatic system cancer	0.000611	0.00157	CcSEcCtD
Levomilnacipran—Headache—Vincristine—lymphatic system cancer	0.000607	0.00156	CcSEcCtD
Levomilnacipran—Nausea—Carmustine—lymphatic system cancer	0.000603	0.00155	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—lymphatic system cancer	0.000601	0.00154	CcSEcCtD
Levomilnacipran—Vomiting—Mitoxantrone—lymphatic system cancer	0.0006	0.00154	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000597	0.00153	CcSEcCtD
Levomilnacipran—Rash—Mitoxantrone—lymphatic system cancer	0.000595	0.00153	CcSEcCtD
Levomilnacipran—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000595	0.00152	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—lymphatic system cancer	0.000594	0.00152	CcSEcCtD
Levomilnacipran—Headache—Mitoxantrone—lymphatic system cancer	0.000592	0.00152	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—lymphatic system cancer	0.00058	0.00149	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—lymphatic system cancer	0.000576	0.00148	CcSEcCtD
Levomilnacipran—Nausea—Vincristine—lymphatic system cancer	0.000576	0.00148	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—lymphatic system cancer	0.000565	0.00145	CcSEcCtD
Levomilnacipran—Nausea—Mitoxantrone—lymphatic system cancer	0.000561	0.00144	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—lymphatic system cancer	0.000543	0.00139	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—lymphatic system cancer	0.000516	0.00132	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—lymphatic system cancer	0.000499	0.00128	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—lymphatic system cancer	0.000491	0.00126	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000487	0.00125	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—lymphatic system cancer	0.000467	0.0012	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000461	0.00118	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000461	0.00118	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—lymphatic system cancer	0.000457	0.00117	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000455	0.00117	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—lymphatic system cancer	0.000448	0.00115	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—lymphatic system cancer	0.00044	0.00113	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—lymphatic system cancer	0.000426	0.00109	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—lymphatic system cancer	0.000422	0.00108	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—lymphatic system cancer	0.000419	0.00108	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—lymphatic system cancer	0.000418	0.00107	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—lymphatic system cancer	0.000414	0.00106	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—lymphatic system cancer	0.000409	0.00105	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000406	0.00104	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—lymphatic system cancer	0.000406	0.00104	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000385	0.000986	CcSEcCtD
Levomilnacipran—Urticaria—Methotrexate—lymphatic system cancer	0.000374	0.000958	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—lymphatic system cancer	0.000372	0.000953	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—lymphatic system cancer	0.000372	0.000953	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000347	0.000888	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—lymphatic system cancer	0.000338	0.000865	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—lymphatic system cancer	0.000333	0.000853	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—lymphatic system cancer	0.000322	0.000825	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—lymphatic system cancer	0.000311	0.000797	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—lymphatic system cancer	0.000299	0.000767	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—lymphatic system cancer	0.000297	0.00076	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—lymphatic system cancer	0.000296	0.00076	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—lymphatic system cancer	0.000295	0.000755	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—lymphatic system cancer	0.000279	0.000716	CcSEcCtD
